Elan Corporation, plc (ELN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. The company focuses on the research, development, manufacture and sale of advanced therapies in neurology, autoimmune diseases and severe pain. The company operates business through two units, namely, BioNeurology and Elan Drug Technologies (EDT). BioNeurology business of Elan focuses on the research, development, and commercial activities related to neurodegenerative diseases; while its EDT unit is engaged in drug delivery business. EDT offers NanoCrystal technology for compounds with poor water solubility and customized oral drug technologies. The company has manufacturing and marketing facilities in Ireland and the US, and is headquartered in Dublin, Ireland.

Elan Corporation, plc (ELN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's mergers and acquisitions (M&As), partnerships and financings. The report provides detailed information on mergers and acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including mergers and acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as mergers and acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 10
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Year, 2006 to YTD 2012 11
Elan Corporation, plc, Pharmaceuticals and Healthcare Deals By Type, 2006 to YTD 2012 12
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Region, 2006 to YTD 2012 13
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2006 to YTD 2012 14
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 15
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 16
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 17
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 18
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 19
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 20
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals Summary, 2006 to YTD 2012 21
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deal Details 23
Partnerships 23
University of Cambridge Enters Into Joint Venture Agreement With Elan 23
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 25
Elan Enters Into Collaboration With Pharmaceutical Product Development 27
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 29
Elan Corporation Amends Its Collaboration With Transition Therapeutics 30
PharmatrophiX Enters Into Co-Development Agreement With Elan 31
Circ Pharma Enters Into Co-Development Agreement With Elan 32
Graffinity Pharmaceuticals Enters Into Research Agreement With Elan 33
Azur Pharma Enters Into Co-Development Agreement With Elan 34
Elan Enters Into Co-Development Agreement With Transition Therapeutics 35
Archemix Enters Into Research And Development Agreement With Elan 36
Licensing Agreements 37
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 37
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan 38
Ariadne Enters Into Licensing Agreement With Elan Pharmaceuticals 39
Zogenix Enters Into Licensing Agreement With Elan 40
GeneGo Enters Into Licensing Agreement With Elan Pharmaceuticals 41
Amarin Enters Into Licensing Agreement With Elan 42
Nitromed Enters Into Licensing Agreement With Elan Pharma 43
Elan And AstraZeneca Enter Into Licensing Agreement With Abbott 44
EntreMed Enters Into Licensing Agreement With Elan 45
Equity Offering 46
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million 46
Elan Completes Private Placement Of $885 Million 47
Debt Offering 49
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million 49
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million 50
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million 51
Elan Completes Debt Offering Of Senior Notes For $150 Million 52
Elan Completes Debt Offering Of 8.875% Senior Notes For $465 Million 53
Asset Transactions 54
Azur Pharma Acquires PRIALT From Elan Pharmaceuticals 54
Johnson and Johnson Acquires Assets And Rights To Alzheimer’s Immunotherapy Program From Elan 55
Eisai Acquires European Rights To Prialt From Elan 57
Elan Corporation, plc - Key Competitors 58
Key Employees 59
Locations And Subsidiaries 61
Head Office 61
Other Locations and Subsidiaries 61
Recent Developments 62
Strategy And Business Planning 62
Feb 23, 2011: Elan And PPD Announce Global Business Relationship In Drug Development 62
Oct 04, 2010: Elan To Launch Manufacturing Services Business In Paris 62
Apr 19, 2010: Elan Announces Exploration Of EDT Separation 63
Aug 06, 2009: PharmatrophiX Forms Global Collaboration With Elan 63
Jul 02, 2009: JandJ, Elan Sign Agreement For Alzheimer’s Immunotherapy Program 63
Financial Announcements 64
Oct 27, 2011: Elan Reports Revenue Of $328.5m In Q3 2011 64
Jul 27, 2011: Elan Reports Total Revenue Of $333.5m For Q2 2011 65
Apr 20, 2011: Elan Reports Net Income Of $68.2m For Q1 2011 65
Feb 08, 2011: Elan Reports Net Loss Of $52.2m For Q4 2010 65
Oct 27, 2010: Elan Reports Net Loss Of $43.6 Million For Q3 2010 66
Oct 27, 2010: Elan Reports Total Revenues Of $281.4 Million For Q3 2010 66
Jul 22, 2010: Elan Reports Net Loss Of $213.1 Million For Q2 2010 68
Apr 21, 2010: Elan Reports Net Loss Of $102.6 Million For Q1 2010 68
Feb 10, 2010: Elan Reports Revenue Of $1 Billion In 2009 68
Oct 21, 2009: Elan Reports Net Income Of $52.3 Million For Q3 2009 70
Jul 21, 2009: Elan Reports Q2, 2009 Results 70
Jul 21, 2009: Elan Reports Net Loss Of $68.2 Million In Q2 2009 70
Apr 22, 2009: Elan Q1 2009 Net Loss Increases 71
Feb 10, 2009: Elan Reports Net Income Of $169.5 Million For Q4 2008 71
Oct 23, 2008: Elan Reports Third Quarter 2008 Financial Results 71
Jul 24, 2008: Elan Reports Second Quarter 2008 Financial Results 72
Jul 07, 2008: Elan Announces Webcast Of Second Quarter 2008 Financial Results 72
Apr 24, 2008: Elan Reports First Quarter 2008 Financial Results 72
Feb 13, 2008: Elan Reports Fourth Quarter And Full-Year 2007 Financial Results 73
Oct 25, 2007: Elan Reports Third Quarter 2007 Financial Results 73
Jul 26, 2007: Elan Reports Second Quarter 2007 Financial Results 74
Apr 24, 2007: Elan Reports First Quarter 2007 Financial Results 74
Mar 30, 2007: Elan Announces Dates For Upcoming Corporate Events And Filing Of Annual Report For Year Ended December 31, 2006 76
Feb 20, 2007: Elan Reports Fourth Quarter And Full-Year 2006 Financial Results 76
Oct 25, 2006: Elan Reports Third Quarter 2006 Financial Results 78
Aug 01, 2006: Elan Reports Second Quarter 2006 Financial Results 79
May 04, 2006: Elan Reports First Quarter 2006 Financial Results 80
Jan 31, 2006: Elan Reports Fourth Quarter And Full-Year 2005 Financial Results 80
Oct 27, 2005: Elan Reports Third Quarter 2005 Financial Results 81
Sep 29, 2005: Elan To File Interim Six Month Ifrs Financials With The Irish And London Stock Exchanges 81
Jul 28, 2005: Elan Reports Second Quarter 2005 Financial Results 82
Apr 28, 2005: Elan Reports First Quarter 2005 Financial Results 82
Feb 08, 2005: Elan Reports Fourth Quarter And Full-Year 2004 Financial Results 83
May 13, 2004: Elan Reports First Quarter 2004 Financial Results 83
Feb 18, 2004: Elan Reports Fourth Quarter 2003 And Full-Year Financial Results; Elan Provides Financial Guidance For 2004; Execution Momentum Continues With Key RandD Milestones 84
Nov 12, 2003: Elan Reports Third Quarter 2003 Financial Results 85
Sep 17, 2003: Elan Reports Second Quarter 2003 Financial Results 87
Jul 16, 2003: Elan Update On Filing Of 2002 Annual Report On Form 20-F 89
Jun 26, 2003: Elan To File For Extension Of Time To File Annual Report On Form 20-F 89
Apr 30, 2003: Elan Announces First Quarter 2003 Financial Results And Recovery Plan Update 90
Feb 05, 2003: Elan Reports Fourth Quarter 2002 And Full-Year Financial Results And Recovery Plan Update 92
Oct 30, 2002: Elan Reports Third Quarter 2002 Financial Results And Recovery Plan Update 93
Sep 30, 2002: Elan Announces Payment Under Guarantee And Provides Third Quarter Update 95
Jul 31, 2002: Elan Reports Second Quarter 2002 Financial Results 96
Jul 01, 2002: Elan To File 2001 Annual Report On Form 20-F With Sec Today 98
May 02, 2002: Elan Reports First Quarter 2002 Financial Results 98
Apr 22, 2002: Elan Announces Webcast Of First Quarter 2002 Financial Results 100
Feb 04, 2002: Elan Reports 2001 Financial Results 100
Jan 28, 2002: Elan Responds To Recent Stock Activity - Confirms Consensus Estimatest For 2001 101
Jan 28, 2002: Elan Announces Webcast Of Fourth-Quarter And Full-Year 2001 Financial Results 101
Oct 25, 2001: Elan Reports Record Third Quarter Results 102
Jul 24, 2001: Elan Reports Record Second Quarter 2001 Financial Results 103
Apr 23, 2001: Elan Reports Record First Quarter 2001 Financial Results 104
Jan 29, 2001: Elan Reports Record 2000 Financial Results 105
Oct 19, 2000: Elan Announces Record Third Quarter 2000 Results 106
Jul 19, 2000: Elan Announces Record Second Quarter 2000 Results 107
Apr 27, 2000: Elan Announces Record 2000 First Quarterly Results 108
Feb 07, 2000: Elan Announces Record 1999 Results 109
Research And Development 110
Dec 12, 2011: University College Dublin And Elan Announce Initiative To Create Leadership In Biotechnology 110
Nov 28, 2011: University Of Cambridge And Elan Launch Cambridge-Elan Centre For Research Innovation And Drug Discovery 111
Feb 23, 2011: Elan And PPD Announce Global Business Relationship In Drug Development 111
Corporate Communications 111
Sep 15, 2011: Elan Announces Board Changes 111
Dec 06, 2010: Elan Appoints Robert Ingram As Chairman 112
Jul 06, 2010: Elan Appoints Eliseo Salinas As Executive Vice President And Chief Medical Officer 113
Apr 19, 2010: Elan Announces Board Changes 113
May 29, 2009: Elan Appoints Renee Tannenbaum As Chief Commercial Officer 113
May 12, 2009: Elan Appoints Richard Pilnik To Board 114
May 08, 2003: Elan Announces Receipt Of Ftc Letter Regarding Skelaxin 114
Legal and Regulatory 115
Mar 29, 2011: Intellipharmaceutics Provides Update On Activities Related To 30mg Generic Version Of Focalin XR 115
Feb 24, 2011: Elan And Celgene Settle Agreement Related To ABRAXANE 115
Jul 15, 2010: Elan Reaches Agreement In Principle For Settlement Of Investigation Of Past Zonegran Sales And Marketing Activities 115
May 16, 2000: Elan Announces Court Decision Affirming Non-Infringement 116
May 16, 2000: Elan Announces Court Decision Affirming Non-Infringement 116
Government and Public Interest 117
Aug 24, 2010: Biogen Idec And Elan Corporation Announce Publication Of Data On Anti-JCV Antibody Assay In Annals Of Neurology 117
Jun 03, 2010: Elan Announces CEO Agreement 117
Sep 14, 2009: Elan Amends Terms Of Transaction With Johnson and Johnson 118
Aug 06, 2009: Elan Files Lawsuit Against Biogen Idec 118
Product News 119
Dec 29, 1999: Elan Submits Nda For Ziconotide 119
Dec 28, 2004: Elan Receives Fda Approval For Prialt (Ziconotide Intrathecal Infusion) For Severe Chronic Pain 119
Dec 21, 2007: Elan And Transition Therapeutics Dose First Patient In Phase 2 Clinical Study Of Elnd005 (Azd-103) In Alzheimers Disease 120
Dec 21, 2007: Elan And Wyeth Dose First Patient In North America In Phase 3 Program For Bapineuzumab (Aab-001) In Alzheimers Disease 121
Dec 21, 2004: Biogen Idec And Elan Announce Head-To-Head Study Comparing Safety And Efficacy Of Tysabri To Rebif 121
Dec 18, 2001: Elan And Biogen Begin Phase Iii Clinical Trials Of Antegren (Natalizumab) In Multiple Sclerosis And Crohns Disease 122
Dec 16, 1999: Elans Betabloc Enters Clinical Studies For Treatment Of Alzheimers Disease 123
Dec 15, 2009: Elan And Transition Therapeutics Announce Modifications To Elnd005 Phase Ii Clinical Trials In Alzheimers Disease 123
Dec 15, 2006: Elan And Biogen Idec Submit Supplemental Biologics License Application To The Fda For The Approval Of Tysabri As A Treatment For Crohns Disease 124
Dec 11, 2000: Fda Approves Elans Myobloc The First Type B Botulinum Toxin Therapy To Be Approved 124
Dec 04, 2009: Elan Drug Technologies Announces Submission By Janssen-Cilag Of Marketing Authorisation Application In Europe For Paliperidone Palmitate For The Treatment Of Schizophrenia Using Elans Nanocrystal Technology 124
Nov 23, 2004: Fda Grants Accelerated Approval Of Tysabri, Formerly Antegren, For The Treatment Of Multiple Sclerosis 124
Nov 17, 2005: Biogen Idec And Elan Announce Fda Acceptance Of Supplemental Biologics License Application And Priority Review Designation For Tysabri(R) In Multiple Sclerosis 125
Nov 16, 2007: Chmp Adopts Negative Opinion On Appeal On European Application For Natalizumab For The Treatment Of Crohns Disease 126
Nov 09, 2001: Fda Approves Elans Migraine Drug Frova (Frovatriptan Succinate) 126
Nov 06, 2000: European Approval Recommended For Elans Neurobloc 127
Oct 29, 2007: Elan Announces The Johnson and Johnson Pharmaceutical Research and Development Submission Of A New Drug Application To The Fda For Paliperidone Palmitate Using Elans Proprietary Nanocrystal Technology 127
Oct 27, 2009: Subset Data From Two Randomized Phase 3 Trials Show Tysabri Significantly Reduces Rates Of Hospitalization In Patients With Moderate-To-Severe Crohns Disease 128
Oct 24, 2006: Tysabri Maintained Remission In Patients With Moderate-To-Severe Crohns Disease Treated For Longer Than Two Years According To Data Presented This Week 128
Oct 20, 2008: Elan And Transition Therapeutics Achieve Patient Enrollment Target In Phase 2 Clinical Study Of Elnd005 (Azd-103) In Alzheimers Disease 129
Oct 15, 2007: Elan And Biogen Idec Announce That Fda Will Extend Regulatory Review Period For Tysabri(R) For Crohns Disease 129
Oct 11, 2007: New Tysabri Data To Be Presented At The European Committee For Treatment And Research In Multiple Sclerosis 129
Oct 06, 2006: New Pharmacoeconomic Data On Tysabri Demonstrate Significant Reduction In Steroid Use And Hospitalizations In Patients With Multiple Sclerosis 130
Oct 04, 2006: Health Canada Grants Approval Of Tysabri(Tm) (Natalizumab) For The Treatment Of Multiple Sclerosis Following Priority Review 131
Sep 29, 2006: New Data Presented At Ectrims Congress Show Tysabri Has Sustained Effect On Relapse Rate In Multiple Sclerosis Patients Treated For Up To Three Years 132
Sep 28, 2006: New Data On Tysabri Presented At Ectrims Congress Demonstrate Significant Improvement In Cognitive Function In Patients With Multiple Sclerosis 133
Sep 26, 2005: Biogen Idec And Elan Submit Supplemental Biologics License Application To The Fda For Tysabri(R) In Multiple Sclerosis 133
Sep 20, 2005: Elan And Biogen Idec Provide An Update On Tysabri(R) 134
Sep 19, 2008: Tysabri Demonstrates Sustained Improvement In Functional Outcomes In Multiple Sclerosis Patients According To New Post-Hoc Analysis 134
Sep 10, 2002: Elan Patents For Transgenic Mice Found Valid 135
Sep 05, 2008: Elan And Biogen Idec Initiate First Clinical Trial Of Tysabri In Oncology 135
Sep 04, 2002: Elan Announces Approval Of New Versions Of Skelaxin And Tizanidine 136
Aug 30, 2000: Elan Announces First U.S. Approval For Its Nanocrystal Technology 136
Aug 29, 2003: Fda Approves New Dosage Strengths Of Elans Zonegran 136
Aug 20, 2007: Tysabri Demonstrates Significant Health-Related Quality-Of-Life Improvements For Multiple Sclerosis Patients In Study Published In Annals Of Neurology 137
Aug 17, 2000: Elan And Biogen To Collaborate On Development And Commercialization Of Antegren (Natalizumab) 137
Aug 09, 2005: Biogen Idec And Elan Announce Tysabri(R) Safety Evaluation Update 138
Jul 31, 2007: Joint Fda Advisory Committee Recommends Approval Of Tysabri For The Treatment Of Moderate To Severe Crohns Disease 139
Jul 31, 2002: Elan Announces Recovery Plan 139
Jul 29, 2008: Elan And Wyeth Present Encouraging Results From Phase 2 Clinical Trial Of Bapineuzumab At International Conference On Alzheimers Disease 141
Jul 26, 2004: Fda Accepts Biologics License Application For Antegren For Multiple Sclerosis 143
Jul 26, 1999: Targeted Genetics Forms Partnership With Elan To Develop Advanced Gene Delivery Technologies. 143
Jul 26, 1999: Elan To Develop Antegren For The Chronic Treatment Of Multiple Sclerosis 144
Jul 24, 2003: Analysis Of Antegren Phase Iii Induction Clinical Trial In Crohns Disease Completed 144
Jul 23, 2007: Tysabri(R) Celebrates One-Year Anniversary As A Treatment For Multiple Sclerosis 146
Jul 18, 2005: Two-Year Sentinel Data Evaluating Tysabri(R) In Addition To Avonex(R) Reinforce Efficacy In Multiple Sclerosis 146
Jul 13, 2009: Elan And Transition Therapeutics Announce Phase 1 Data Showing Elnd005 Achieves Desired Concentrations In Brain Tissue And Cerebrospinal Fluid 147
Jun 30, 2005: Tysabri(R) Phase Iii Induction Trial In Crohns Disease Meets Primary Endpoint; Tysabri Induced Statistically Significant Response And Remission In Patients With Active Disease 148
Jun 29, 2006: Tysabri Receives Approval In European Union For The Treatment Of Relapsing Remitting Forms Of Multiple Sclerosis 148
Jun 28, 2004: Fda Designates Antegren Biologics License Application For Priority Review As A Treatment For Multiple Sclerosis; Application Under Accelerated Approval Guidelines 149
Jun 28, 2004: Elan Files Amendment To New Drug Application For Prialt For Severe Chronic Pain Based On Additional Efficacy And Safety Data 149
Jun 28, 2002: Elan Announces Eon Labs Have Obtained Fda Approval For The 4 Mg Dosage Form Of Zanaflex 149
Jun 28, 2000: Elan Announces Receipt Of Fda Approvable Letter For Ziconotide 150
Jun 17, 2008: Elan And Wyeth Announce Encouraging Top-Line Results From Phase 2 Clinical Trial Of Bapineuzumab For Alzheimers Disease 150
Jun 06, 2002: Fda Grants Marketing Clearance For Ritalin La, A Once-Daily Formulation Of Ritalin For Adhd That Lasts Through The Entire School Day 151
Jun 05, 2006: Fda Approves The Reintroduction Of Tysabri For The Treatment Of Relapsing Forms Of Multiple Sclerosis 152
Jun 04, 2004: Biogen Idec And Elan Submit Application To The European Medicines Agency For Approval Of Antegren For Multiple Sclerosis Based On One-Year Data 154
Jun 03, 1999: Elan Receives Tentative Approval For Generic To Adalat Cc 154
May 31, 2009: Elan, Biogen Idec Study Reveals Positive Results For Tysabri 154
May 31, 2009: Subset Data From Two Randomized Phase 3 Trials Show Tysabri(R) Significantly Improves Health-Related Quality Of Life For Crohns Disease Patients With Prior Exposure Or Inadequate Response To Anti-Tnfa Therapy 155
May 29, 2007: Elan And Biogen Idec Announce A Fda Advisory Committee Meeting To Review Tysabri: For The Treatment Of Crohns Disease 155
May 25, 2004: Biogen Idec And Elan Submit Biologics License Application To The Fda For Approval Of Antegren For Multiple Sclerosis Based On One-Year Data 156
May 23, 2001: Antegren (Natalizumab) Phase Ii Data Show Promising Results In Crohns Disease 156
May 21, 2007: Elan And Wyeth To Initiate Phase 3 Clinical Trial Of Bapineuzumab (Aab-001) In Alzheimers Disease 157
May 18, 2004: Elan And Biogen Idec Announce Intention To Submit Antegren For Approval For Crohns Disease In Europe 158
May 03, 2007: Data Presented At The American Academy Of Neurologys Annual Meeting Provide Update On Utilization And Safety Of Tysabri In Patients With Multiple Sclerosis 158
May 02, 2000: Fda Issues Approvable Letter For Elans Anti Migraine Drug Frovatriptan 159
Apr 28, 2006: Chmp Issues Positive Opinion For Tysabri As A Treatment For Relapsing-Remitting Multiple Sclerosis 159
Apr 27, 1999: Elan Announces Product Acquisition 159
Apr 23, 2009: Elan And Transition Therapeutics Receive Key Patent For Alzheimers Disease Treatment With Elnd005 160
Apr 21, 1999: Elans Neurobloc (Botulinum Toxin Type B) Achieves Statistical Significance In Phase Iii Clinical Trials In The Treatment Of Cervical Dystonia 160
Apr 14, 1999: Elan Announces Outcome Of Pre-Nda Meeting With Fda Relating To Ziconotide 161
Apr 13, 2005: Positive One-Year Data From Sentinel Trial Evaluating Addition Of Tysabri To Avonex Presented At American Academy Of Neurology Meeting 162
Apr 12, 2005: Tysabri Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings And Show Significant Reduction In Risk Of Disability Progression 163
Apr 06, 2006: New Data On Tysabri Demonstrate Significant Effects On Health-Related Quality Of Life Measures In Patients With Multiple Sclerosis 163
Apr 02, 2009: Elan And Wyeth Plan To Amend Bapineuzumab Phase 3 Protocols 165
Mar 30, 2005: Elan And Biogen Idec Announce Tysabri Update 165
Mar 29, 2006: Biogen Idec And Elan Announce Re-Initiation Of Tysabri Clinical Trial Dosing In Multiple Sclerosis 166
Mar 28, 2002: Elan And Ucb Announce Agreement To Co-Promote New Migraine Drug Frova; Product To Be Launched Q’2 2002 166
Mar 28, 2000: Fda Approves Zonegran; Offers A New Option To Epilepsy Patients With Inadequately Controlled Seizures 167
Mar 26, 1999: Vanguard Medica And Elan Announce Acceptance Of New Drug Application For Frovatriptan For Review By Fda 167
Mar 23, 2004: Biogen Idec And Elan Announce Intention To Submit Antegren For Approval For Multiple Sclerosis In Europe 167
Mar 22, 2006: Biogen Idec And Elan Announce That Fda Will Extend Regulatory Review Period For The Reintroduction Of Tysabri For Multiple Sclerosis 168
Mar 21, 2002: Elan Receives Fda Approval Of Avinza A Once-Daily Capsule For Chronic, Moderate-To-Severe Pain 168
Mar 14, 2000: Elan To Commence U.K. Multiple Dose Clinical Study With Betabloc In Alzheimer Patients 168
Mar 08, 2006: Fda Advisory Committee Unanimously Recommends Reintroduction Of Tysabri For The Treatment Of Relapsing Forms Of Multiple Sclerosis 169
Mar 01, 2006: Tysabri Two-Year Phase Iii Multiple Sclerosis Clinical Trial Results And Safety Evaluation Published In New England Journal Of Medicine; Tysabri Currently Under Review With U.S. And European Regulatory Authorities 169
Feb 29, 2000: Ziconotide Nda Filed By Fda Six-Month Review Agreed 169
Feb 28, 2010: Neuroimaging Technique Supports Reduction In Amyloid-Beta In Brains Of Patients Suffering From Alzheimers Disease Treated With Bapineuzumab 170
Feb 28, 2005: Biogen Idec And Elan Announce Voluntary Suspension Of Tysabri 170
Feb 22, 2005: Elan Receives Approval From The European Commission To Market Prialttm (100 Micrograms/Ml Solution For Infusion) For Severe Chronic Pain 171
Feb 18, 2004: Biogen Idec And Elan Announce Intention To Submit Antegren For Approval For Multiple Sclerosis Based On One-Year Data 171
Feb 17, 2005: Tysabri Two-Year Monotherapy Trial Demonstrates Significant Impact On Disability Progression And Relapse Rate In Multiple Sclerosis 172
Feb 15, 2006: Tysabri Multiple Sclerosis Clinical Trial Hold Lifted By Fda; Biogen Idec And Elan To Resume Clinical Trial Dosing In Ms 172
Feb 09, 2009: Ms Patients Treated With Tysabri Remain Free Of Disease Activity For Two Years, According To Data Published In The Lancet Neurology 173
Feb 03, 2005: Japanese Patent Office Issues Patent Certificate To Elan For Its Nanocrystal-Tm- Technology 174
Feb 03, 2004: Elan And Biogen Idec Announce Initiation Of Antegren Rheumatoid Arthritis Trial; Phase Ii Study To Begin First Half Of 2004 174
Feb 01, 1999: Vanguard Medica And Elan Announce U.S. Regulatory Submission Of Miguard (Frovatriptan) 175
Jan 29, 2004: Elan And Biogen Idec Announce Antegren (Natalizumab) Phase Iii Maintenance Trial In Crohns Disease Met Its Primary Endpoint 175
Jan 25, 2010: Elan Drug Technologies Welcomes The Nda Approval Of Ms Drug Ampyra(Tm) (Dalfampridine) Extended Release Tablets 176
Jan 23, 2006: Biogen Idec And Elan Announce Notification Of Fda Advisory Committee Meeting To Review Tysabri For The Treatment Of Multiple Sclerosis 177
Jan 22, 2001: Elan And Biogen Announce Positive Phase Ii Results For Antegren (Natalizumab) In Multiple Sclerosis And Crohns Disease 177
Jan 17, 2002: Elan And Ahp Provide An Update On The Phase 2a Clinical Trial Of An-1792 178
Jan 14, 2008: Fda Approves Tysabri For The Treatment Of Moderate-To-Severe Crohns Disease 179
Jan 13, 2009: Elan Clarifies Duration Of Bapineuzumab Phase 3 Trials 179
Jan 12, 2005: Elans Proprietary Nanocrystal Technology Is Used By Johnson and Johnson Pharmaceutical Research and Development, L.L.C. (JandJ Prd) In Phase Iii Clinical Trial Of Paliperidone Palmitate 179
Jan 11, 1999: Elan Submits Product License Application For Neurobloc And Complete Response For Zonegran 180
Jan 07, 2004: Elan Achieves Primary Endpoint In Prialt Phase Iii Trial 180
Jan 04, 1999: Elan Receives Fda Approval For Nicotine Otc Patch; Perrigo To Market The Product 181
Jan 02, 2003: Antegren (Natalizumab) Clinical Study Results Published In New England Journal Of Medicine Show Promising Data On Disease Remission And Quality Of Life For Patients With Crohns Disease 181
Jan 02, 2003: Clinical Study Results Published In The New England Journal Of Medicine Show Promising Data On Antegren (Natalizumab) In The Treatment Of Relapsing Forms Of Multiple Sclerosis 183
Clinical Trials 184
Aug 09, 2010: Elan And Transition Announce Topline Results From Phase II Study Of ELND005 For Alzheimer's Disease 184
Dec 15, 2009: Elan Corporation And Transition Therapeutics Announces Phase II Study Modifications Of ELND005 For The Treatment Of Alzheimer's Disease 185
Jul 13, 2009: Elan and Transition Therapeutics Announces Phase 1 Data Of ELND005 185
Jan 09, 2008: Amarin Announces Successful Outcome of Nasal Lorazepam Study 185
Dec 21, 2007: Elan And Transition Therapeutics Dose First Patient In Phase 2 Clinical Study of ELND005 (AZD-103) In Alzheimer's Disease 186
Aug 30, 2007: Transition Therapeutics Inc. Announces Completion Of Phase I Clinical Studies Of ELND-005/AZD-103 186
Other Significant Developments 186
Oct 04, 2010: Elan To Launch Manufacturing Services Business At CPHI World Meeting In Paris 186
Appendix 188
Methodology 188
About GlobalData 188
Contact Us 188
Disclaimer 188

List of Tables

Elan Corporation, plc, Pharmaceuticals and Healthcare, Key Facts, 2010 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Year, 2006 to YTD 2012 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Region, 2006 to YTD 2012 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2006 to YTD 2012 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Year, 2006 to YTD 2012 11
Elan Corporation, plc, Pharmaceuticals and Healthcare Deals By Type, 2006 to YTD 2012 12
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Region, 2006 to YTD 2012 13
Elan Corporation, plc, Deals By Therapy Area, 2006 to YTD 2012 14
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 15
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 15
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 16
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 16
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 17
Elan Corporation, plc, Pharmaceuticals and Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 17
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 18
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 18
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 19
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 19
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 20
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 20
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals Summary, 2006 to YTD 2012 21
University of Cambridge Enters Into Joint Venture Agreement With Elan 23
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 25
Elan Enters Into Collaboration With Pharmaceutical Product Development 27
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 29
Elan Corporation Amends Its Collaboration With Transition Therapeutics 30
PharmatrophiX Enters Into Co-Development Agreement With Elan 31
Circ Pharma Enters Into Co-Development Agreement With Elan 32
Graffinity Pharmaceuticals Enters Into Research Agreement With Elan 33
Azur Pharma Enters Into Co-Development Agreement With Elan 34
Elan Enters Into Co-Development Agreement With Transition Therapeutics 35
Archemix Enters Into Research And Development Agreement With Elan 36
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 37
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan 38
Ariadne Enters Into Licensing Agreement With Elan Pharmaceuticals 39
Zogenix Enters Into Licensing Agreement With Elan 40
GeneGo Enters Into Licensing Agreement With Elan Pharmaceuticals 41
Amarin Enters Into Licensing Agreement With Elan 42
Nitromed Enters Into Licensing Agreement With Elan Pharma 43
Elan And AstraZeneca Enter Into Licensing Agreement With Abbott 44
EntreMed Enters Into Licensing Agreement With Elan 45
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million 46
Elan Completes Private Placement Of $885 Million 47
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million 49
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million 50
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million 51
Elan Completes Debt Offering Of Senior Notes For $150 Million 52
Elan Completes Debt Offering Of 8.875% Senior Notes For $465 Million 53
Azur Pharma Acquires PRIALT From Elan Pharmaceuticals 54
Johnson and Johnson Acquires Assets And Rights To Alzheimer’s Immunotherapy Program From Elan 55
Eisai Acquires European Rights To Prialt From Elan 57
Elan Corporation, plc, Key Competitors 58
Elan Corporation, plc, Key Employees 59
Elan Corporation, plc, Subsidiaries 61

List of Figures

Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals by Type, 2006 to YTD 2012 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals by Year, 2006 to YTD 2012 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Licensing Deals by Phase, 2006 to YTD 2012 1
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Year, 2006 to YTD 2012 11
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals by Type, 2006 to YTD 2012 12
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Region, 2006 to YTD 2012 13
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2006 to YTD 2012 14

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Rhinovirus Infection - Pipeline Review, H1 2014

Rhinovirus Infection - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Rhinovirus Infection - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Rhinovirus Infection - Pipeline Review, H1 2014', provides an overview of the Rhinovirus Infection's therapeutic pipeline. ...

Rhabdomyosarcoma - Pipeline Review, H1 2014

Rhabdomyosarcoma - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Rhabdomyosarcoma - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Rhabdomyosarcoma - Pipeline Review, H1 2014', provides an overview of the Rhabdomyosarcoma's therapeutic pipeline. This report ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.